FDA Inspects Manufacturing Facilities in Satara and East Brunswick
What happened
The United States Food and Drug Administration inspected Rubicon Research Limited's manufacturing facility in Satara from October 5 to October 9, 2026. Following the inspection, a Form 483 containing one procedural observation was issued for the Satara site. The FDA also inspected the company's manufacturing facility in East Brunswick, New Jersey, in May 2026.
From equitybulls.com
Why it matters
Regulatory inspections by the FDA are critical for pharmaceutical companies seeking U.S. market approval. The outcome of these inspections affects the ability of companies to launch products in the United States.
Pharmaceutical companies are currently seeking FDA approval to launch products in the U.S. market.
From equitybulls.com
Who's involved
- United States Food and Drug AdministrationConducted the regulatory inspection of the manufacturing facilities.
- East BrunswickLocation of the acquired manufacturing facility that was inspected by the FDA.
Keep exploring
The entities involved
-
United States Food and Drug Administration
agency of the US Department of Health and Human Services
Nothing else this week.
-
East Brunswick
township in Middlesex County, New Jersey, United States
Nothing else this week.